


C L A I M S


1. A compound of the formula [I]:

5




wherein

10




15



X is bond, $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, $-\text{C}(=\text{O})-$, $-\text{O}-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{S}-$
 $\text{N}-$
 R_7 (in which R⁷ is hydrogen or lower alkyl),
Y is bond, $-\text{O}-(\text{CH}_2)_n-$ (in which n is 1, 2, 3 or 4),
 $-(\text{CH}_2)_m-$ (in which m is 1, 2, 3 or 4),

20



Z is cyano, tetrazolyl, (benzylsulfonyl)carbamoyl,
benzoylsulfamoyl, formyl, carboxy or protected
carboxy,

25

R¹ is hydrogen, lower alkyl or halogen,

R² is hydrogen or an amino protective group,

R³ is hydrogen or lower alkyl,

R⁴ is hydrogen or lower alkyl,

30 R⁵ and R⁸ are each independently hydrogen, halogen,
hydroxy, lower alkyl, lower alkenyl, lower alkoxy,
hydroxy(lower)alkoxy, mono(or di or
tri)halo(lower)alkoxy, lower alkoxy(lower)alkoxy,
lower alkenyloxy, cyclo(lower)alkyloxy,
cyclo(lower)alkyl(lower)alkoxy, benzyloxy, phenoxy,

35

lower alkylthio, cyclo(lower)alkylthio, lower alkylsulfonyl, cyclo(lower)alkylsulfonyl, amino, mono(or di)(lower)alkylamino, mono(or di or tri)halo(lower)alkyl, cyano, piperidinyl or phenyl,

5 R⁶ is hydrogen, lower alkyl or halogen,



R⁹ is hydrogen or lower alkyl, and

i is 1 or 2,

provided that


(1) when X is bond, -CH₂-, -CH(OH)- or -C=O-,

10





15 then R⁵ is not hydrogen, or

(2) when i is 1,



20 or a salt thereof.

2. A compound of claim 1, wherein




25 X is bond, -O-, -OCH₂-, -S- or -N- (in which R⁷ is
R⁷)

30 hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1, 2, 3 or 4),
-(CH₂)_m- (in which m is 1, 2, 3 or 4),


35



Z is carboxy or lower alkoxy carbonyl,
 R¹ is hydrogen or halogen,
 R² is hydrogen,
 R³ is hydrogen or lower alkyl,
 5 R⁴ is hydrogen,
 R⁵ is halogen, hydroxy, lower alkyl, lower alkoxy,
 hydroxy(lower)alkoxy, mono(or di or
 tri)halo(lower)alkoxy, lower alkoxy(lower)alkoxy,
 lower alkenyloxy, cyclo(lower)alkyloxy, phenoxy or
 10 phenyl,
 R⁶ is hydrogen,
 R⁸ is hydrogen or lower alkyl,
 R⁹ is hydrogen or lower alkyl, and
 i is 1 or 2.

15

3. A compound of claim 2, wherein



20

X is bond, -O-, -OCH₂-, -S- or $\begin{matrix} -N- \\ | \\ R^7 \end{matrix}$ (in which R⁷ is
 25 hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1 or 2) or
 -(CH₂)_m- (in which m is 1 or 2),

Z is carboxy or lower alkoxy carbonyl,

R¹ is hydrogen or halogen,

30

R² is hydrogen,

R³ is hydrogen or lower alkyl,

R⁴ is hydrogen,

R⁵ is halogen, hydroxy, lower alkyl or lower alkoxy,

R⁶ is hydrogen,


35

R⁸ is hydrogen or lower alkyl,


R^9 is hydrogen or lower alkyl, and
i is 1.

4. A compound of claim 3, wherein

5



10



X is bond,

Y is bond,

Z is carboxy or lower alkoxy carbonyl,

R^1 is hydrogen or halogen,

15

R^2 is hydrogen,

R^3 is hydrogen or lower alkyl,

R^4 is hydrogen,

R^5 is halogen, hydroxy, lower alkyl or lower alkoxy,

R^6 is hydrogen,

20

R^8 is hydrogen or lower alkyl,

R^9 is hydrogen or lower alkyl, and

i is 1.

25

5. A compound of claim 4, which selected from the group consisting of

30

(1) $4'-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid,$

(2) $4'-[(2R)-2-[(2R)-2-Phenyl-2-hydroxyethyl]amino]-propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid,$

(3) $4'-[(2R)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid,$

35

(4) $4'-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic$

acid,

(5) $4' - [2 - [(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid,$

5 (6) $4' - [2 - [(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid,$

(7) $4' - [(2R)-2 - [(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]-amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid,$

10 (8) $4' - [2 - [(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]-amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid,$

(9) $4' - [(2R)-2 - [(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid,$


15 (10) $4' - [2 - [(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid, and$

(11) $4' - [2 - [(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-biphenyl-4-carboxylic acid,$


20 or a pharmaceutically acceptable salt thereof.

6. A process for preparing a compound of claim 1,
or a salt thereof,
25 which comprises,


(i) reacting a compound [II] of the formula:



wherein R^1 , R^9 and \circled{A} are each as defined in claim 1,
with a compound [III] of the formula:




wherein , X , Y , Z , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 and
5 i are each as defined in claim 1,
or a salt thereof, to give a compound [I] of the
formula:




10 wherein , , X , Y , Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 ,
 R^8 , R^9 and i are each as defined in claim 1,
15 or a salt thereof,

(ii) subjecting a compound [Ia] of the formula:



20 wherein , , X , Y , Z , R^1 , R^3 , R^4 , R^5 , R^6 , R^8 ,
25 R^9 and i are each as defined in claim 1,
and

R_a^2 is an amino protective group,
or a salt thereof, to elimination reaction of the amino
protective group, to give a compound [Ib] of the
30




5

wherein   X , Y , Z , R^1 , R^3 , R^4 , R^5 , R^6 , R^8 ,

R^9 and i are each as defined in claim 1,
or a salt thereof,

10

(iii) reacting a compound [IV] of the formula:




15

wherein \textcircled{A} , R^1 , R^2 , R^3 , R^4 , R^6 , R^9 and i are each as defined in claim 1,

or a salt thereof, with a compound [V] of the formula:


20



25

wherein , Y, Z, R⁵ and R⁸ are each as defined in claim 1.


or a salt thereof, to give a compound [Ic] of the formula:



35

R^9 and i are each as defined in
claim 1,
or a salt thereof,

5 (iv) reacting a compound [IV] of the formula:



10

wherein $\circlearrowleft A \circlearrowright$, R^1 , R^2 , R^3 , R^4 , R^6 , R^9 and i are each as defined in claim 1,
or a salt thereof, with a compound [VI] of the formula:


15



20

wherein $\circlearrowleft B \circlearrowright$, Y , Z , R^5 and R^8 are each as defined in
claim 1, and
 X_1 is a leaving group,
or a salt thereof, to give a compound [Ic] of the
formula:

25




30

wherein $\circlearrowleft A \circlearrowright$, $\circlearrowleft B \circlearrowright$, Y , Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 ,
 R^8 , R^9 and i are each as defined in
claim 1,
or a salt thereof,

35

(v) reacting a compound [VII] of the formula:

5



[VII]


10

wherein \textcircled{A} , R^1 , R^2 , R^3 , R^4 , R^6 , R^9 and i are each as defined in claim 1,

X_2 is a leaving group,

or a salt thereof, with a compound [V] of the formula:

15




[V]

wherein \textcircled{B} , Y , Z , R^5 and R^8 are each as defined in claim 1,

20

or a salt thereof, to give a compound [Id] of the formula:

25



[Id]


wherein \textcircled{A} , \textcircled{B} , Y , Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 ,

30

R^9 and i are each as defined in claim 1,
or a salt thereof, and

(vi) subjecting a compound [Ie] of the formula:

5




10

wherein , , X, Y, R¹, R³, R⁴, R⁵, R⁶, R⁸,

R⁹ and i are each as defined in claim 1,
R¹⁰ is lower alkyl, and

R^{2a} is an amino protective group,
or a salt thereof, to deesterification reaction, to
give a compound [If] of the formula:

15




20

wherein , , X, Y, R¹, R³, R⁴, R⁵, R⁶, R⁸,

R⁹ and i are each as defined in claim 1,
and

R^{2a} is defined above,
or a salt thereof, and then subjecting the compound
[If] above to elimination reaction of amino protective
group, to give a compound [Ig] of the formula:

30



35

wherein , , X, Y, R¹, R³, R⁴, R⁵, R⁶, R⁸,

or a salt thereof.

7. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.
8. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.
9. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
10. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as selective β_3 adrenergic receptor agonists.
11. A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

25

30

35